Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation investigational neuromodulator product, DaxibotulinumtoxinA for Injection. We are building a premium category in facial aesthetics, focused on differentiated and improved outcomes, a compelling value proposition and an elevated experience for HCPs and patients.
DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval in 2020. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including forehead lines and lateral canthal lines (crow’s feet), as well as in three therapeutic indications in need of new, longer-lasting treatment options – cervical dystonia, adult upper limb spasticity and plantar fasciitis, with plans to study migraine.
To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD financial technology (fintech) platform, which includes integrated smart payment, subscription and loyalty digital services.
Revance has also partnered with Mylan N.V. to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace.
Revance is dedicated to making a difference by transforming patient experiences and is positioned to be an innovation leader not only in aesthetics, but also in therapeutics.
We believe in leaving bureaucracy behind. We value speed, audacity, grit and empathy, and empower our teams to reimagine the status quo.